Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00800007 · ClinicalTrials.gov registry record · Phase 1
Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus
A Phase 1 study, sponsored by Anza Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00800007: Clinical Trial Phase 1 study, sponsored by Anza Therapeutics.
NCT00800007 is a Phase 1 study that was terminated before completion, run by Anza Therapeutics. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00800007, a Phase 1 study, was terminated before completion, sponsored by Anza Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, immunogenicity, and antiviral effects of multiple intravenous doses of ANZ-521 in patients with chronic Hepatitis C virus.
Interventions
- DRUG Placebo
- DRUG ANZ-521
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
Why NCT00800007 stopped before completion
NCT00800007 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00800007 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00800007 about?
NCT00800007 is a clinical study titled "Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus". The purpose of this study is to evaluate the safety, immunogenicity, and antiviral effects of multiple intravenous doses of ANZ-521 in patients with chronic Hepatitis C virus.
What is the current status of trial NCT00800007?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2008-11. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00800007?
The interventions under investigation include: Placebo (DRUG), ANZ-521 (DRUG).
Who is sponsoring clinical trial NCT00800007?
This trial is sponsored by Anza Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00800007's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia